Phage–Antibiotic Synergy Enhances Biofilm Eradication and Survival in a Zebrafish Model of Pseudomonas aeruginosa Infection
Open Access
- 1 June 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (11) , 5337
Abstract
Pseudomonas aeruginosa is a gram-negative opportunistic pathogen that poses a significant threat due to its increasing multidrug resistance, particularly in clinical settings. This study aimed to isolate and characterize a novel bacteriophage, phiLCL12, from hospital wastewater and evaluate its potential in combination with antibiotics to combat P. aeruginosa infections and biofilm formation. Transmission electron microscopy revealed that phiLCL12 possesses a long contractile tail. The isolated phage exhibited a broad host range of 82.22% and could adsorb up to 98% of its target within 4 min. It was effective against multidrug-resistant strains at both high and low multiplicities of infection (MOIs) levels in lysis tests. Taxonomic classification was determined using PhaGCN2 and Whole genomic analysis, and the results identified phiLCL12 as a member of the Pbunavirus. In vitro experiments demonstrated that phiLCL12 significantly enhanced biofilm clearance and inhibited biofilm formation when combined with sub-inhibitory concentrations of imipenem. Furthermore, in vivo experiments using a zebrafish model showed that phage–antibiotic synergy (PAS) improved survival rate compared to antibiotic treatment alone. This study demonstrates that phiLCL12 is effective in both eradicating and preventing P. aeruginosa biofilm formation. The combination of phiLCL12 and imipenem provides a synergistic effect, significantly enhancing survival outcomes in a zebrafish model. These findings highlight the potential of phage–antibiotic synergy as a promising therapeutic strategy against biofilm-associated infections.Keywords
Funding Information
- Tzu Chi University (TCMRC-P-111005)
This publication has 66 references indexed in Scilit:
- High prevalence of multidrug‐resistant Pseudomonas aeruginosa carrying integron and exoA, exoS, and exoU genes isolated from burn patients in Ahvaz, southwest Iran: A retrospective studyHealth Science Reports, 2024
- Temporal and geographical prevalence of carbapenem-resistant Pseudomonas aeruginosa and the in vitro activity of ceftolozane/tazobactam and comparators in Taiwan—SMART 2012–2021Journal of Global Antimicrobial Resistance, 2023
- An intensive care unit outbreak with multi-drug-resistant Pseudomonas aeruginosa – spotlight on sinksJournal of Hospital Infection, 2023
- Emergence of hypervirulent Pseudomonas aeruginosa pathotypically armed with co-expressed T3SS effectors ExoS and ExoUhLife, 2023
- Multicenter surveillance of antimicrobial susceptibilities and resistance mechanisms among Enterobacterales species and non-fermenting Gram-negative bacteria from different infection sources in Taiwan from 2016 to 2018Journal of Microbiology, Immunology and Infection, 2022
- Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategiesBiotechnology Advances, 2019
- Piperacillin and ceftazidime produce the strongest synergistic phage–antibiotic effect in Pseudomonas aeruginosaArchives of Virology, 2018
- Pseudomonas aeruginosa in hospital water systems: biofilms, guidelines, and practicalitiesJournal of Hospital Infection, 2015
- Role of exoenzyme S in chronicPseudomonas aeruginosa lung infectionsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1985
- Pseudomonas aeruginosa and Escherichia coli in sewage and fresh waterWater Research, 1980